Long-acting sustained-release preparation containing pramipexole and preparation method therefor

By combining praxol with pharmaceutically acceptable salts and polymer materials, microspheres, sustained release granules and subcutaneous implants were prepared, and the problem of short release cycle of existing praxol tablets was solved, achieving long-term stability Release improves efficacy and medication safety and enhances patient compliance.

WO2023221814A9PCT designated stage expired Publication Date: 2024-11-07SICHUAN KELUN PHARMA RES INST CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/092960
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-05-16
Filing Date
2023-05-09
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

The release cycle of existing praxol tablets is short and requires three daily medications, which causes inconvenience to patients with Parkinson's disease. Patients with missed taking symptoms such as memory loss, tremors in their hands and feet, which leads to worsening of the condition and lacks long-term delayed release. Formulated to improve compliance and efficacy.

Method used

Using praxol combined with pharmaceutically acceptable salt and polymer materials such as PLGA, PLA, mPEG-PLA, etc., to prepare microspheres, sustained release granules and subcutaneous implants, through oil-phase formulation, emulsification and hot melt extrusion technology , form a long-acting sustained-release preparation with stable drug loading and high encapsulation rate, and achieve long-term and stable release of the drug.

Benefits of technology

The long-term stable release of pramixol drugs was achieved for 1 week, 2 weeks or even 1 month, reducing sudden release, improving clinical efficacy and medication safety, and enhancing patient compliance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2023092960-FTAPPB-I100001
    Figure PCTCN2023092960-FTAPPB-I100001
  • Figure PCTCN2023092960-FTAPPB-I100002
    Figure PCTCN2023092960-FTAPPB-I100002
  • Figure PCTCN2023092960-FTAPPB-I100003
    Figure PCTCN2023092960-FTAPPB-I100003
Patent Text Reader

Abstract

Disclosed is a long-acting sustained-release preparation pharmaceutical composition containing pramipexole, comprising a pharmaceutically acceptable salt of pramipexole and a pharmaceutical high polymer material. The preparation is selected from a microsphere, a sustained-release particle, and a subcutaneous implant. The pharmaceutically acceptable salt of pramipexole is selected from erucate, stearate, oleate, α-linolenate, heptadecanoate, embonate, and palmitate. The high polymer material is selected from PLGA, PLA, mPEG-PLA, and PEG-PLA-PEG. The present invention belongs to the technical field of pharmaceutical preparations and solves the problems of short release period and poor release effect of pramipexole in the prior art.
Need to check novelty before this filing date? Find Prior Art

Description

A long-acting sustained-release preparation containing pramipexole and its preparation method Field of the Invention

[0001] The present invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a long-acting sustained-release preparation containing pramipexole and a preparation method thereof.

[0002] Background of the Invention

[0003] According to a study by Qi S, Yin P, Wang L, et al. (Prevalence of Parkinson's Disease: A Community-Based Study in China. Mov Disord. Published online August 14, 2021: mds.28762.doi:10.1002 / mds.28762), China's socioeconomic and demographic structures have undergone significant changes over the past few decades, entering a stage of profound aging. The prevalence of Parkinson's disease (PD) in people aged 60 and older is 1.37% (95% confidence interval, 1.02%-1.73%), and it is estimated that the total number of people with PD in China may be as high as 3.62 million.

[0004] Pramipexole is a second-generation, potent, selective non-ergot-based dopamine D2 receptor agonist that is clinically used to treat primary Parkinson's disease. It can cover the entire stage of disease treatment until the late stage. It can significantly improve the motor symptoms of patients with early and late Parkinson's disease, and can also improve the depressive symptoms associated with Parkinson's disease patients. It is the first choice drug recommended by domestic and international Parkinson's disease treatment guidelines.

[0005] Parkinson's disease patients often experience symptoms such as memory loss, tremors in the hands and feet, and difficulty swallowing, leading to widespread missed doses and worsening of their condition. Currently available pramipexole hydrochloride tablets have a short release cycle, requiring three doses daily and requiring frequent dosing, which is extremely inconvenient for Parkinson's patients. Therefore, research and development of sustained-release formulations of pramipexole that can deliver stable, long-term release, such as once a week, two weeks, one month, or even three months, is crucial for improving patient compliance and enhancing clinical treatment efficacy.

[0006] SUMMARY OF THE INVENTION

[0007] Based on the above problems, the present invention aims to provide a long-acting sustained-release preparation containing pramipexole, which has stable drug loading, high encapsulation efficiency, can achieve long-term and stable drug release, and control the burst release to a very low limit, which is beneficial to clinical efficacy and drug safety.

[0008] In one aspect, the present invention provides a long-acting sustained-release formulation containing pramipexole, which comprises a pharmaceutically acceptable salt of pramipexole and a pharmaceutical polymer material;

[0009] The preparation is selected from microspheres, sustained-release microparticles and subcutaneous implants;

[0010] The pharmaceutically acceptable salt of pramipexole is selected from erucate, stearate, oleate, α-linolenate, pearlate, pamoate and palmitate; preferably, the pharmaceutically acceptable salt of pramipexole is selected from erucate, stearate, oleate, α-linolenate, pearlate and palmitate; more preferably, the pharmaceutically acceptable salt of pramipexole is selected from erucate, stearate, oleate, pearlate and palmitate;

[0011] The polymer material is selected from PLGA, PLA, mPEG-PLA and PEG-PLA-PEG.

[0012] In some embodiments, in the pharmaceutically acceptable salt of pramipexole provided herein, the molar ratio of pramipexole to erucic acid, stearic acid, oleic acid, α-linolenic acid, pearlitic acid, or palmitic acid is 1:1.

[0013] In some embodiments, in the pharmaceutically acceptable salt of pramipexole provided by the present invention, the molar ratio of pramipexole to pamoic acid is 1:1 or 2:1; preferably, the molar ratio of pramipexole to pamoic acid is 2:1.

[0014] In some embodiments, in the sustained-release preparation provided by the present invention, the content of pramipexole (calculated as free compound) accounts for 10-55% of the total weight of the preparation; the content of the polymer material accounts for 90-45% of the total weight of the preparation.

[0015] In some embodiments, in the sustained-release preparation provided by the present invention, the polymer material is PLGA, and its molecular weight is 10,000 to 100,000 Da, wherein the LA:GA block ratio of PLGA is 5:95 to 95:5.

[0016] In some preferred embodiments, in the sustained-release preparation provided by the present invention, the polymer material is PLGA, the molecular weight of which is 25,000 to 100,000 Da, wherein the LA:GA block ratio of PLGA is 50:50 to 85:15.

[0017] In some preferred embodiments, in the sustained-release preparation provided by the present invention, the type of PLGA used is 2.5A, 3A, 5A, 4.5A, 4.5E, 5E, 7A, 7E or 8E.

[0018] In some embodiments, in the sustained-release preparation provided by the present invention, the polymer material is PLA, and its molecular weight is 10,000 to 100,000 Da.

[0019] In some embodiments, in the sustained-release preparation provided by the present invention, the polymer material is mPEG-PLA, wherein the molecular weight of mPEG in mPEG-PLA is 1000-4000 Da, and the molecular weight of PLA is 10,000-100,000 Da.

[0020] In some embodiments, in the sustained-release preparation provided by the present invention, the polymer material is PEG-PLA-PEG, wherein the molecular weight of PEG is 1000-4000 Da, and the molecular weight of PLA is 10000-100000 Da.

[0021] In a second aspect, the present invention provides a long-acting sustained-release preparation containing pramipexole, wherein the preparation is a microsphere, and the active ingredient is pramipexole pearlate, palmitate, erucate, stearate or oleate.

[0022] In a second aspect, the present invention provides a long-acting sustained-release preparation containing pramipexole, wherein the preparation is a microsphere, and the active ingredient is pramipexole pearlylate or palmitate; each unit of the preparation contains 1 to 3 parts of pramipexole (calculated as a free compound) and 7 to 9 parts of PLGA, the LA:GA block ratio of the PLGA is 50:50, and the theoretical drug loading is 10% to 30%; preferably, the theoretical drug loading is 15% to 25%.

[0023] In some embodiments, in the pramipexole-containing microspheres provided by the present invention, the PLGA is 50:50 3A or 50:50 4.5E.

[0024] In a third aspect, the present invention provides a long-acting sustained-release preparation containing pramipexole, wherein the preparation is a microsphere, and the active ingredient is pramipexole erucate, stearate, or oleate; each unit of the preparation contains 2 to 4 parts of pramipexole (calculated as a free compound) and 8 to 6 parts of PLGA, the LA:GA block ratio of the PLGA is 75:25-85:15, and the theoretical drug loading is 20% to 40%; preferably, the theoretical drug loading is 25% to 35%.

[0025] In some embodiments, in the pramipexole-containing microspheres provided by the present invention, the PLGA is 2.5A, 5A, 5E or 7E; preferably, the PLGA is 2.5A, 5A or 7E.

[0026] In some embodiments, in the pramipexole-containing microspheres provided by the present invention, the PLGA is 85:15 2.5A, 75:25 5E, 75:25 5A, or 75:25 7E; preferably, the PLGA is 85:15 2.5A, 75:25 5A, or 75:25 7E.

[0027] In a fourth aspect, the present invention provides a long-acting sustained-release preparation containing pramipexole, wherein the preparation is a microsphere, and the active ingredient is pramipexole erucate, palmitate, or oleate; each unit of the preparation contains 3 to 5.5 parts of pramipexole (calculated as a free compound) and 7 to 4.5 parts of PLGA, the LA:GA block ratio of the PLGA is 75:25-85:15, and the theoretical drug loading is 30% to 55%; preferably, the theoretical drug loading is 35% to 50%, and more preferably, the theoretical drug loading is 35% to 45%.

[0028] In some embodiments, in the pramipexole-containing microspheres provided by the present invention, the PLGA is 4.5A, 7A, 5E or 8E; preferably, the PLGA is 4.5A, 7A or 8E.

[0029] In some embodiments, in the pramipexole-containing microspheres provided by the present invention, the PLGA is 85:15 4.5A, 85:15 5E, 75:25 7A, or 75:25 8E; preferably, the PLGA is 85:15 4.5A, 75:25 7A, or 75:25 8E.

[0030] In a fifth aspect, the present invention provides a long-acting sustained-release preparation containing pramipexole, which is a sustained-release granule. The active ingredient is pramipexole erucate, pamoate, stearate, oleate, palmitate, or pearlesate. Each unit of the preparation contains 1 to 5.5 parts of pramipexole (calculated as a free compound) and 9 to 4.5 parts of PLGA. The LA:GA block ratio of the PLGA is 50:50 to 85:15, and the theoretical drug loading is 20% to 55%.

[0031] In some embodiments, in the sustained-release granules containing pramipexole provided by the present invention, the PLGA is 2.5A, 3A, 5A, 4.5A, 4.5E, 5E, 7A or 7E.

[0032] In a sixth aspect, the present invention provides a long-acting sustained-release preparation containing pramipexole, which is a subcutaneous implant and wherein the active ingredient is pramipexole erucate, pamoate, stearate, oleate, or palmitate. Each unit of the preparation contains 2 to 5.5 parts of pramipexole (calculated as the free compound) and 8 to 4.5 parts of PLGA, wherein the LA:GA block ratio of the PLGA is 50:50 to 85:15 (preferably 75:25 to 85:15), and the theoretical drug loading is 20% to 55%.

[0033] In some embodiments, in the subcutaneous implant containing pramipexole provided herein, the PLGA is 2.5A, 4.5A, 5A, 5E, 7A or 7E.

[0034] In a seventh aspect, the present invention provides a method for preparing the above-mentioned microsphere preparation, comprising the following steps:

[0035] Preparation of the oil phase: adding a pharmaceutically acceptable salt of pramipexole into a first solvent and dissolving it to obtain a first oil phase; dissolving PLGA in a second solvent to obtain a second oil phase.

[0036] Preparation of external aqueous phase: Add PVA into water and dissolve it for later use.

[0037] Oil phase mixing: stirring and mixing the first oil phase and the second oil phase to obtain a mixed oil phase.

[0038] Emulsification: First, fill the external water phase into the online shearing machine, mix the external water phase and the mixed oil phase at a speed of 5000-13000 rpm, and shear and emulsify.

[0039] Solidification: The sheared solution is gradually heated according to a temperature rise curve under stirring to evaporate the solvent, solidify, and freeze-dry to form microspheres.

[0040] In a preferred embodiment, in the above solidification step, the sheared solution is gradually heated according to a temperature rise curve under stirring to volatilize the solvent, solidified, sieved, and freeze-dried to form microspheres.

[0041] In some embodiments, in the method for preparing microspheres provided by the present invention, the first solvent is selected from one or more of dichloromethane, benzyl alcohol, methanol, ethanol, isopropanol, tert-butanol, NMP, DMSO and DMF; preferably dichloromethane or benzyl alcohol.

[0042] In some embodiments, in the method for preparing microspheres provided by the present invention, the second solvent is selected from one or more of dichloromethane, chloroform and ethyl acetate; preferably dichloromethane or chloroform.

[0043] In some embodiments, in the method for preparing microspheres provided by the present invention, the mass concentration (g / ml) of pramipexole in the first oil phase is 0.05-0.9, preferably 0.05-0.7; the mass concentration (g / ml) of PLGA in the second oil phase is 0.1-0.4.

[0044] In an eighth aspect, the present invention provides a method for preparing the above-mentioned sustained-release granules, comprising the following steps:

[0045] Mixing a pharmaceutically acceptable salt of pramipexole with PLGA and adding the mixture to a hot melt extrusion feed funnel;

[0046] Extrusion: Use hot melt extruder, extrude at 100 rpm under 60 bar, and control the torque to 7-8 N.cm;

[0047] Granulation: After extrusion, the wire is drawn and granulated using a pelletizer;

[0048] Crushing: The granulated product is crushed to 50-100 μm, preferably 60-100 μm, using a low-temperature ball mill to obtain sustained-release granules.

[0049] In some embodiments, in the method for preparing sustained-release particles, in the extrusion step, the feed temperature and the propulsion temperature are both room temperature, the mixing temperature is controlled at 70-140°C, the degassing temperature is the same as the mixing temperature, the extrusion temperature is controlled at 55-120°C, and the die temperature is controlled at 50-75°C.

[0050] In some embodiments, in the method for preparing sustained-release particles, in the extrusion step, the feed temperature and the propulsion temperature are both room temperature, the mixing temperature is controlled at 100-110°C, the degassing temperature is the same as the mixing temperature, the extrusion temperature is controlled at 85-110°C, and the die temperature is controlled at 65-72°C.

[0051] In a ninth aspect, the present invention provides a method for preparing the above-mentioned subcutaneous implant, comprising the following steps:

[0052] Mixing a pharmaceutically acceptable salt of pramipexole with PLGA and adding the mixture to a hot melt extrusion feed funnel;

[0053] Extrusion: Use hot melt extruder, extrude at 100 rpm under 60 bar, and control the torque to 7-8 N.cm;

[0054] Granulation: After extrusion, the mixture is drawn into wire and granulated with a pelletizer to obtain a subcutaneous implant.

[0055] In some embodiments, in the method for preparing a subcutaneous implant, in the extrusion step, the feed temperature and the propulsion temperature are both room temperature, the mixing temperature is controlled at 70-140°C, the degassing temperature is the same as the mixing temperature, the extrusion temperature is controlled at 55-120°C, and the die temperature is controlled at 65-75°C.

[0056] In some embodiments, in the method for preparing a subcutaneous implant, in the granulation step, the die size is set to 3 mm and the pelletizing length is set to 35 mm.

[0057] Detailed Description of the Invention

[0058] Definitions and terms

[0059] As described in the present invention, "microspheres" refer to tiny spherical preparations formed by dispersing drugs in a high molecular weight polymer matrix.

[0060] As described herein, "sustained-release granules," also known as long-acting sustained-release granules or long-acting sustained-release microparticles, are a type of formulation distinct from microspheres. These particles are obtained by dispersing the drug within a polymer matrix through pulverization or other methods. Compared to microspheres, sustained-release granules are irregular polyhedrons.

[0061] As described in the present invention, "subcutaneous implant", also known as subcutaneous implant, refers to a type of preparation in which a drug-loaded preparation is made into a rod shape and buried under the skin to slowly release the drug.

[0062] As for the polymer materials involved in the present invention, PLGA is called polylactic acid-glycolic acid copolymer in Chinese, wherein LA represents lactic acid and GA represents glycolic acid; PLA is called polylactic acid in Chinese; mPEG-PLA is called methoxypolyethylene glycol-polylactic acid in Chinese; PEG-PLA-PEG is called polyethylene glycol-polylactic acid-polyethylene glycol in Chinese; PEG is called polyethylene glycol in Chinese.

[0063] For the polymer materials referred to herein, 5050PLGA 3A is abbreviated as 5050 3A, where "5050" indicates a 50:50 LA:GA block ratio, "3" indicates an intrinsic viscosity (IV) of approximately 0.3 dL / g, "A" indicates carboxyl endcapping, and "E" indicates ester endcapping. PLA 2A represents PLA with an IV of approximately 0.2 dL / g and carboxyl endcapping. mPEG-PLA2000-20000 represents a diblock copolymer of PLA and mPEG, where the molecular weight of mPEG is 2000 Da and the molecular weight of PLA is 20,000 Da.

[0064] As for the polymer materials involved in the present invention, the molecular weight of the polymer is its statistical average value. Although the molecular weight described in the present invention is a fixed value, it is actually a range value for the polymer. This range value is usually ±10% of the molecular weight determination value. For example, the molecular weight is 50,000 Da, and the actual molecular weight range is 45,000 Da to 55,000 Da; the molecular weight is 100,000 Da, and the actual molecular weight range is 90,000 Da to 110,000 Da, and so on.

[0065] As described in the present invention, the theoretical drug loading represents the feed ratio of API to polymer (eg, PLGA), and the theoretical drug loading = API mass / (API mass+polymer mass)*100%, where API is calculated as free pramipexole compound.

[0066] As described in the present invention, encapsulation efficiency = actual drug loading / theoretical drug loading * 100%.

[0067] As used herein, "parts" mentioned when describing the content of formulation components refer to parts by weight.

[0068] As used herein, the molecular weight of a polymeric material is the weight average molecular weight.

[0069] As described in the present invention, PVA is called polyvinyl alcohol in Chinese. BRIEF DESCRIPTION OF THE DRAWINGS

[0070] Figure 1 In vivo pharmacokinetic curves (formulations 1, 2, and 11)

[0071] Figure 2 Enlarged 24h release curve (Formulations 1, 2, and 11)

[0072] Figure 3 In vivo pharmacokinetic release curves (Formulations 27 and 38)

[0073] Figure 4. Enlarged 24h in vivo release curve (Formulations 27 and 38)

[0074] Figure 5 In vivo pharmacokinetic release curves (formulations 53 and 61)

[0075] Figure 6. Enlarged images of the 24h in vivo release curves (formulations 53 and 61). DETAILED DESCRIPTION

[0076] To make the technical solutions and advantages of the present invention more clear, the technical solutions in the embodiments of the present invention are described clearly and completely below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer were followed. Reagents or instruments used where the manufacturer is not specified are conventional products that can be purchased commercially.

[0077] The Chinese names of the English chemical abbreviations involved in the embodiments of the present invention are as follows:

[0078] The molecular weight of polymer preparations is mainly characterized by Mw and PDI. PDI represents the distribution of molecular weight, which is generally between 1.5 and 2.0, indicating that the molecular weight distribution is uniform.

[0079] Example 1 Preparation of microsphere preparation containing pramipexole

[0080] Table 1 Microsphere Prescription and Material Table

[0081] Preparation method:

[0082] Preparation of the oil phase: Weigh the API raw materials according to the above formula feeding table. The API feeding amount is calculated as the free compound of pramipexole. The molar ratio of pramipexole to each acid radical of the salt form listed in Table 1 is 1:1. Add solvent 1 and dissolve to obtain the first oil phase. Weigh the prescribed amount of PLGA and add solvent 2 to dissolve to obtain the second oil phase.

[0083] Preparation of external aqueous phase: weigh the prescribed amount of PVA and add it into water, dissolve it and set aside for use;

[0084] Oil phase mixing: stirring the first oil phase and the second oil phase at 4-40° C. for 5-50 minutes to obtain a mixed oil phase;

[0085] Emulsification: First, the external aqueous phase is filled into an online shearing machine (IKA 2000 / 03 + DR shearing head), and the external aqueous phase and the mixed oil phase are mixed at a speed of 8000 rpm and sheared and emulsified;

[0086] Solidification: The sheared solution is gradually heated according to a temperature rise curve under stirring to evaporate the solvent, solidified, sieved, and freeze-dried.

[0087] Example 2 Preparation of sustained-release granules containing pramipexole

[0088] Table 2 Prescription and material list of sustained-release granules

[0089] Preparation method:

[0090] Weighing: Accurately weigh the API and PLGA shown in the table above. The API dosage is calculated as the free compound of pramipexole. The molar ratio of pramipexole to pamoic acid is 2:1, and the molar ratio of pramipexole to the acid radicals of the remaining salt forms listed in Table 2 is 1:1. Physically mix the two and add them to the hot melt extrusion feeding funnel.

[0091] Extrusion: Select Thermo Fisher Pharma 11 and parallel counter-rotating twin-screws, start the hot melt extruder, set the feed temperature, propulsion temperature, mixing, degassing, extrusion and die temperature according to the above list, set the pressure threshold: 60 bar, extrusion speed: 100 rpm, torque threshold: 8 N.cm, and start automatic feeding, mixing and extrusion after setting.

[0092] Granulation: Set the membrane size to 3mm and the pelletizing length to 35mm for extrusion. After extrusion (the first drop of extrudate), manually use a glass rod to pull the wire onto the pelletizer roller to start pelletizing.

[0093] Crushing: Pour the granulated particles into the ball mill and start grinding. Take samples every 5 minutes to monitor the particle size. When the target particle size (D 50 =50~100 μm), then stop grinding to obtain sustained-release particles.

[0094] Example 3 Preparation of subcutaneous implants containing pramipexole

[0095] Table 3 Subcutaneous implant prescription material list

[0096] Preparation method:

[0097] Weighing: Accurately weigh the API and PLGA shown in the table above. The API dosage is calculated as the free compound of pramipexole. The molar ratio of pramipexole to pamoic acid is 2:1, and the molar ratio of pramipexole to the acid radicals of the remaining salt forms listed in Table 3 is 1:1. Physically mix the two and add them to the hot melt extrusion feeding funnel.

[0098] Extrusion: Use a Thermo Fisher Pharma 11 with parallel counter-rotating twin-screws. Start the hot melt extruder and set the feed temperature, propulsion temperature, mixing temperature, degassing temperature, extrusion temperature, and die temperature according to the table above. Set the pressure threshold to 60 bar, the extrusion speed to 100 rpm, and the torque threshold to 8 N.cm. Once configured, begin automatic feeding, mixing, and extrusion.

[0099] Granulation: Select the membrane specifications listed in the table above and set the pelletizing length as indicated. After extrusion (the first drop of extrudate), manually draw the extrudate with a glass rod onto the pelletizer rollers and begin pelletizing to obtain the subcutaneous implant.

[0100] Comparative Example 1 Preparation of microsphere preparation containing pramipexole

[0101] Table 4 Comparative Example Microsphere Preparation Prescription and Ingredients

[0102] Comparative Examples 1 to 5 in the above table were prepared according to the preparation method of Example 1, with a molar ratio of pramipexole to pamoic acid of 2:1, and a molar ratio of pramipexole to hydrochloric acid or behenic acid of 1:1. In the preparation of Comparative Example 3, dichloromethane, chloroform, ethyl acetate, methanol, ethanol, isopropanol, tert-butanol, DMSO, DMF, acetone, and tetrahydrofuran were used as solvent 1 to dissolve pramipexole behenate, but all failed to dissolve the pramipexole behenate effectively, and a microsphere preparation could not be prepared.

[0103] Test Example 1: Quality Assessment of Microsphere Preparations

[0104] Detection method: The actual drug loading, encapsulation efficiency, particle size, residual solvent content and in vitro release of the above microsphere examples and comparative samples were examined.

[0105] In vitro release assay method: The microspheres were placed in a vial, added to a PBS buffer solution with a pH of 7.4±0.1, and placed in a shaking water bath at 37±0.5°C. Samples were taken at different time points, and the drug content released into the buffer solution was detected by HPLC.

[0106] The "in vitro burst release" in this investigation test refers to the cumulative release rate on the first day of in vitro release. The test results are as follows:

[0107] Table 5 Microsphere preparation example sample quality inspection results

[0108] Table 6 Microsphere preparation comparative sample quality inspection results

[0109] The investigation revealed that the microspheres prepared in Examples 1, 2, 19, 21, 22, and 45 all had high encapsulation efficiencies, with virtually no burst release. Comparative Examples 1 and 2 (hydrochloride salt, free compound) exhibited significant API migration during the preparation process, resulting in severely low encapsulation efficiencies, accompanied by significant burst release and poor appearance. The microspheres in Comparative Example 5 exhibited poor sphericity, multiple pores, a loose structure, and an uneven in vitro release profile. Comparative Example 4 exhibited significant burst release, posing clinical risks.

[0110] Test Example 2 Quality Assessment of Sustained-Release Granule Preparations

[0111] Testing method: The actual drug loading, encapsulation efficiency, particle size, and in vitro release of the above-mentioned sustained-release granules were examined. The test results are as follows:

[0112] Table 7 Quality test results of sustained-release granules

[0113] It can be seen from the data in the above table that the sustained-release granule samples prepared in each embodiment meet the requirements in terms of pharmaceutical performance, and the burst release amount is at a relatively low level.

[0114] Test Example 3: Quality Inspection of Subcutaneous Implants

[0115] Testing method: The actual drug loading, encapsulation efficiency and in vitro release of the above subcutaneous implant samples were examined. The test results are as follows:

[0116] Table 8 Subcutaneous implant quality test results

[0117] It can be seen from the above results that the subcutaneous implants prepared in each example meet the requirements for various pharmaceutical indicators, and the burst release is at a relatively low level.

[0118] Experimental Example 4 In vivo pharmacokinetic investigation

[0119] Male rats weighing approximately 250g were selected and randomly divided into groups of 5. Each group received the drug via intramuscular injection only once. Venous blood was collected before and after administration to determine the plasma concentration of pramipexole. The concentration-time curve was fitted to calculate the pharmacokinetics parameters.

[0120] Scheme 1: The test samples were the samples of Examples No. 1, 2, and 11; the dosage was 4 mg / kg. The test results are shown in Figures 1 and 2.

[0121] Scheme 2: The test samples were samples of Example Nos. 27 and 38, and the dosage was 8 mg / kg. The test results are shown in Figures 3 and 4.

[0122] Scheme 3: The test samples were samples of Example Nos. 53 and 61, and the dosage was 16 mg / kg. The test results are shown in Figures 5 and 6.

[0123] Table 9 Example sample rat in vivo PK test data

[0124] Note: "Burst release" refers to the ratio of exposure on the first day to exposure over the entire cycle. The calculation formula is: Burst release = AUC 0-24 ÷AUC 0-last *100%.

[0125] From the above test results, it can be seen that the long-acting sustained-release preparation of pramipexole prepared by the present invention can achieve long-term stable release of 1 week, 2 weeks or even 1 month without obvious burst release phenomenon, and the blood drug concentration is stable, meeting the requirements of clinical efficacy and medication safety, and can greatly improve patient compliance.

[0126] The present invention provides a long-acting sustained-release formulation containing a pharmaceutically acceptable salt of pramipexole and a method for preparing the same. Those skilled in the art can achieve this by referring to the contents herein and appropriately changing the raw materials, process parameters, and other aspects. The methods and products of the present invention have been described through preferred embodiments. It is apparent that those skilled in the art can modify or appropriately alter and combine the methods and products described herein without departing from the content, spirit, and scope of the present invention to implement the technology of the present invention. It is particularly important to note that all similar substitutions and modifications will be apparent to those skilled in the art and are considered to be included in the spirit, scope, and content of the present invention.

Claims

1. A long-acting sustained-release preparation containing pramipexole, characterized in that: It contains a pharmaceutically acceptable salt of pramipexole and a pharmaceutical polymer material; The preparation is selected from microspheres, sustained-release microparticles and subcutaneous implants; The pharmaceutically acceptable salt of pramipexole is selected from erucate, stearate, oleate, α-linolenate, pearlate, pamoate and palmitate; preferably, the pharmaceutically acceptable salt of pramipexole is selected from erucate, stearate, oleate, α-linolenate, pearlate and palmitate; more preferably, the pharmaceutically acceptable salt of pramipexole is selected from erucate, stearate, oleate, pearlate and palmitate; The polymer material is selected from PLGA, PLA, mPEG-PLA and PEG-PLA-PEG.

2. The long-acting sustained-release preparation according to claim 1, characterized in that The polymer material is PLGA, and its molecular weight is 10000-100000Da, wherein the LA:GA block ratio of PLGA is 5:95-95:5; preferably, the polymer material is PLGA, and its molecular weight is 25000-100000Da, wherein the LA:GA block ratio of PLGA is 50:50-85:15; Alternatively, the polymer material is PLA, and its molecular weight is 10000 to 100000 Da; Alternatively, the polymer material is mPEG-PLA, wherein the molecular weight of mPEG in mPEG-PLA is 1000-4000 Da, and the molecular weight of PLA is 10000-100000 Da; Alternatively, the polymer material is PEG-PLA-PEG, wherein the molecular weight of PEG is 1000-4000 Da, and the molecular weight of PLA is 10000-100000 Da.

3. The long-acting sustained-release preparation according to claim 1 or 2, characterized in that: The preparation is a microsphere, and the active ingredient is pramipexole pearlylate or palmitate; each unit of the preparation contains 1 to 3 parts of pramipexole as a free compound and 9 to 7 parts of PLGA, the LA:GA block ratio of PLGA is 50:50, and the theoretical drug loading is 10% to 30%, preferably, the theoretical drug loading is 15% to 25%.

4. The long-acting sustained-release preparation according to claim 1 or 2, characterized in that: The preparation is a microsphere, and the active ingredient is pramipexole erucate, stearate or oleate; each unit of the preparation contains 2 to 4 parts of pramipexole as a free compound and 8 to 6 parts of PLGA, the LA:GA block ratio of PLGA is 75:25-85:15, and the theoretical drug loading is 20% to 40%, preferably, the theoretical drug loading is 25% to 35%.

5. The long-acting sustained-release preparation according to claim 1 or 2, characterized in that: The preparation is a microsphere, and the active ingredient is pramipexole erucate, palmitate or oleate; each unit of the preparation contains 3 to 5.5 parts of pramipexole as a free compound and 7 to 4.5 parts of PLGA, the LA:GA block ratio of PLGA is 75:25-85:15, and the theoretical drug loading is 30%-55%, preferably, the theoretical drug loading is 35%-50%, and more preferably, the theoretical drug loading is 35%-45%.

6. The long-acting sustained-release preparation according to claim 1 or 2, characterized in that: The preparation is a sustained-release granule, the active ingredient of which is pramipexole erucate, pamoate, stearate, oleate, palmitate or pearlate; each unit of the preparation contains 1 to 5.5 parts of pramipexole as a free compound and 9 to 4.5 parts of PLGA, the LA:GA block ratio of PLGA is 50:50-85:15, and the theoretical drug loading is 20%-55%.

7. The long-acting sustained-release preparation according to claim 1 or 2, characterized in that: The preparation is a subcutaneous implant, and the active ingredient is pramipexole erucate, pamoate, stearate, oleate or palmitate; each unit of the preparation contains 2 to 5.5 parts of pramipexole as a free compound and 8 to 4.5 parts of PLGA, the LA:GA block ratio of PLGA is 50:50-85:15, and the theoretical drug loading is 20%-55%.

8. A method for preparing the microspheres according to any one of claims 3 to 5, comprising the following steps: Preparation of the oil phase: adding a pharmaceutically acceptable salt of pramipexole into a first solvent and dissolving the salt to obtain a first oil phase; dissolving PLGA in a second solvent to obtain a second oil phase; Preparation of external water phase: Add PVA into water and dissolve it for later use; Oil phase mixing: stirring and mixing the first oil phase and the second oil phase to obtain a mixed oil phase; Emulsification: First, fill the external water phase into the online shearing machine, mix the external water phase and the mixed oil at a speed of 5000-13000rpm, and shear emulsify; Solidification: The sheared solution is gradually heated up according to a temperature rise curve under stirring to evaporate the solvent, solidify, and freeze-dry to form microspheres; Preferably, in the solidification step, the sheared solution is gradually heated according to a temperature rise curve under stirring to volatilize the solvent, solidified, sieved, and freeze-dried to form microspheres.

9. A method for preparing the sustained-release granules according to claim 6, comprising the following steps: Mixing a pharmaceutically acceptable salt of pramipexole with PLGA and adding the mixture to a hot melt extrusion feed funnel; Extrusion: hot melt extruder, extrusion speed 100rpm at 60bar, control torque 7-8N.cm; Granulation: After extrusion, the wire is drawn and granulated with a pelletizer; Crushing: The granulated product is crushed to 50-100 μm, preferably 60-100 μm, using a low-temperature ball mill to obtain sustained-release particles.

10. A method for preparing the subcutaneous implant of claim 7, comprising the steps of: Mixing a pharmaceutically acceptable salt of pramipexole with PLGA and adding the mixture to a hot melt extrusion feed funnel; Extrusion: hot melt extruder, extrusion speed 100rpm at 60bar, control torque 7-8N.cm; Granulation: After extrusion, the mixture is drawn into wire and granulated with a pelletizer to obtain a subcutaneous implant.